1. Home
  2. GEG vs IMA Comparison

GEG vs IMA Comparison

Compare GEG & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GEG

Great Elm Group Inc.

N/A

Current Price

$1.86

Market Cap

80.9M

Sector

Technology

ML Signal

N/A

IMA

ImageneBio Inc.

N/A

Current Price

$5.52

Market Cap

65.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GEG
IMA
Founded
1994
2019
Country
United States
United States
Employees
N/A
15
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.9M
65.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GEG
IMA
Price
$1.86
$5.52
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
$16.00
AVG Volume (30 Days)
73.9K
23.9K
Earning Date
05-06-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.76
$5.35
52 Week High
$3.51
$17.50

Technical Indicators

Market Signals
Indicator
GEG
IMA
Relative Strength Index (RSI) 30.89 32.41
Support Level N/A N/A
Resistance Level $2.19 $7.17
Average True Range (ATR) 0.09 0.39
MACD -0.01 -0.04
Stochastic Oscillator 18.18 8.66

Price Performance

Historical Comparison
GEG
IMA

About GEG Great Elm Group Inc.

Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.

About IMA ImageneBio Inc.

ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.

Share on Social Networks: